Science Current Events | Science News | Brightsurf.com
 

Cholinesterase inhibitors reduce aggression, wandering and paranoia in Alzheimer's disease

December 10, 2008

INDIANAPOLIS - Cholinesterase inhibitors, used to treat cognitive symptoms of Alzheimer's disease, are also a safe and effective alternative therapy for the behavioral and psychological symptoms of dementia, according to a study that appears in the December 2008 edition of Clinical Interventions in Aging.

Investigators from the Indiana University School of Medicine, the Regenstrief Institute and Wishard Health Services reviewed nine randomized, double-blind, placebo-controlled clinical trials evaluating the effectiveness of three popular cholinesterase inhibitors in managing behavioral and psychological symptoms displayed by patients with Alzheimer's disease.

The researchers report that the trial results indicate cholinesterase inhibitors led to a statistically significant reduction in behavioral and psychological symptoms such as aggression, wandering or paranoia when using the same dosage as administered for improving cognitive impairment.

Nine out of 10 Alzheimer's disease patients display behavioral and psychological symptoms of their disease. The review of the clinical trials revealed that cholinesterase inhibitors are safe, producing no major side effects.

"There is a need for safe alternatives to the anti-psychotic drugs currently used to manage the behavioral and psychological symptoms of Alzheimer's disease. The results of the studies we analyzed are encouraging and suggestive that cholinesterase inhibitors are safe and effective alternatives. However, they are underutilized and typically prescribed for less than three months and for less than 10 percent of patients with Alzheimer's disease. Our findings might provide clinicians with useful data to justify the appropriate use of these medications," said Malaz Boustani, M.D., corresponding author of the Clinical Interventions in Aging paper. Dr. Boustani is assistant professor of medicine at the IU School of Medicine, a Regenstrief Institute research scientist, a research investigator with the IU Center for Aging Research, and chief research officer of the Indianapolis Discovery Network for Dementia.

In Alzheimer's disease there is a decrease in acetylcholine, a chemical in the brain that assists memory, thought and judgment. Cholinesterase inhibitors raise acetylcholine levels. Increased concentrations of acetylcholine in the brain leads to increased communication between nerve cells and may improve or stabilize the symptoms of Alzheimer's disease in the early and moderate stages of progression.

Noll Campbell, PharmD, a clinical pharmacy specialist in geriatric psychiatry with Wishard Health Services and corresponding author of the paper, said that, "This class of medications has already been approved by the Food and Drug Administration to manage symptoms of Alzheimer's-type dementia, although their potential benefits on behavioral symptoms are not frequently identified by many prescribers. Clinical trials of cholinesterase inhibitors have shown benefits in several domains of cognitive function as well as behavioral symptoms associated with dementia, and may improve the management of behavioral problems while reducing the use of more harmful medications that are needed to control behaviors."

Dr. Boustani noted that the vast majority of busy primary care physicians, the doctors who see the majority of patients with Alzheimer's disease, are unaware of the details of the studies analyzed in the Clinical Interventions in Aging paper and he hopes that this new paper, which reviewed the studies, will encourage them to prescribe cholinesterase inhibitors, with its benefits for both cognition and behavior symptoms to their Alzheimer's disease patients.

Indiana University


Related Cholinesterase Inhibitors Current Events and Cholinesterase Inhibitors News Articles


Common medications for dementia could cause harmful weight loss
Medications commonly used to treat dementia could result in harmful weight loss, according to UC San Francisco researchers, and clinicians need to account for this risk when prescribing these drugs to older adults, they said.

AGS unveils revised Choosing Wisely list of topics to talk about with older adults
The American Geriatrics Society (AGS) today released updates to several of its recommendations for the ABIM Foundation's Choosing Wisely® campaign, which raises professional and public awareness about treatments and tests to question and discuss because they may lack efficacy or cause potential harm.

Study shows benefit in activities of daily living and savings in caregiver time with vitamin E
Difficulty with activities of daily living often affect Alzheimer's patients, which is estimated to affect as many as 5.1 million Americans.

Turning Alzheimer's fuzzy signals into high definition
Scientists at the Virginia Tech Carilion Research Institute have discovered how the predominant class of Alzheimer's pharmaceuticals might sharpen the brain's performance.

No evidence drugs, vitamins, supplements help prevent cognitive decline in healthy older adults
A review of published research has found no evidence that drugs, herbal products or vitamin supplements help prevent cognitive decline in healthy older adults.

Many Alzheimer's patients get drugs with opposing effects
You wouldn't brake your car while stepping on the gas-or wash down a sleeping pill with espresso. Yet many people taking common Alzheimer's disease medications-cholinesterase inhibitors-are given medications with anticholinergic properties, which oppose their effects.

New gene test discovered for inherited neuromuscular disorder
Newcastle University scientists have identified a new gene which will allow rapid diagnosis and earlier treatment of a debilitating neuromuscular condition.

Alzheimer's drug boosts perceptual learning in healthy adults
Research on a drug commonly prescribed to Alzheimer's disease patients is helping neuroscientists at the University of California, Berkeley, better understand perceptual learning in healthy adults.

New approach to fighting Alzheimer's shows potential in clinical trial
In the early stages of Alzheimer's disease, patients typically suffer a major loss of the brain connections necessary for memory and information processing.

New approach to fighting Alzheimer's shows potential in clinical trial
In the early stages of Alzheimer's disease, patients typically suffer a major loss of the brain connections necessary for memory and information processing. Now, a combination of nutrients that was developed at MIT has shown the potential to improve memory in Alzheimer's patients by stimulating growth of new brain connections.
More Cholinesterase Inhibitors Current Events and Cholinesterase Inhibitors News Articles

Cholinesterases and Cholinesterase Inhibitors: Basic Preclinical and Clinical Aspects

Cholinesterases and Cholinesterase Inhibitors: Basic Preclinical and Clinical Aspects
by Ezio Giacobini (Author)


With the collaboration of the most distinguished scholars in this field Professor Giacobini has put together a publication which will convey present knowledge in the field of molecular biology and genetics, biochemistry, cell biology, pharmacology and toxicology as well of clinical applications (particularly in the field of Alzheimer's disease therapy) of cholinesterase inhibitors. In a concise but precise manner it condenses our present knowledge of these enzymes and their inhibitors and helps those who want to understand them as well as to utilize them for therapeutic purposes.

Cholinesterase Inhibitors for the management of Alzheimer Disease

Cholinesterase Inhibitors for the management of Alzheimer Disease
by Preet Anand (Author)


Chemistry is an expanding field and presently, medicinal chemistry branch has flourished at a tremendous rate due to active research in this area of field. Alzheimer‟s disease (AD) is a progressive, neurodegenerative disorder of the brain among the elderly. It constitutes one of the major health problems in developed countries along with cardiovascular disorders and cancer. The impairment in the cholinergic function which deals with learning, memory, behaviour and emotional responses, is due to rapid hydrolysis of ACh by acetylcholinesterase enzyme (AChE). Thus, AChE inhibition has been documented as a critical target for the effective management of AD by an increase in the availability of ACh in the brain regions. Hence the symptomatic management of patients with AD is based on...

Current Research

Current Research
by Egiacobini (Author)


Book by Egiacobini

Morgan and Mikhail's Clinical Anesthesiology, 5th edition

Morgan and Mikhail's Clinical Anesthesiology, 5th edition
by John Butterworth (Author), David C. Mackey (Author), John Wasnick (Author)


The most user-friendly, clinically relevant overview of the practice of anesthesiologyA Doody's Core Title for 2015!Current, concise, and engagingly written, Morgan & Mikhail’s Clinical Anesthesiology, Fifth Edition is a true essential for all anesthesia students and practitioners. This trusted classic delivers comprehensive coverage of the field’s must-know basic science and clinical topics in a clear, easy-to-understand presentation. Indispensable for coursework, exam review, and as a clinical refresher, this trusted text has been extensively updated to reflect the latest research and developments.Here’s why Clinical Anesthesiology is the best anesthesiology resource:NEW full-color presentationNEW chapters on the most pertinent topics in anesthesiology, including anesthesia...

New Therapeutics for Traumatic Brain Injury: Prevention of Secondary Brain Damage and Enhancement of Repair and Regeneration

New Therapeutics for Traumatic Brain Injury: Prevention of Secondary Brain Damage and Enhancement of Repair and Regeneration
by Kim Heidenreich (Editor)


New Therapeutics for Traumatic Brain Injury: Prevention of Secondary Brain Damage and Enhancement of Repair and Regeneration explores traumatic brain injury (TBI), a major cause of death and disability throughout the world. The delayed nature of the secondary injury phase suggests that there is a therapeutic window for pharmacological interventions or other approaches to prevent progressive tissue damage and improve functional outcomes. It is now apparent that therapeutic interventions should entail both protective and repair/regeneration strategies depending on the phase of brain injury. This book describes emerging experimental strategies for the treatment of TBI, including new anti-inflammatory or anti-apoptotic therapeutics that limit brain damage, and novel or repurposed drugs that...

Human Cholinesterases and Anticholinesterases

Human Cholinesterases and Anticholinesterases
by Hermona Soreq (Author), Haim Zakut (Author)


Molecular biological approaches have deepened our understanding of the role that cholinesterases play in regulating the action of the neurotransmitter acetylcholine, in embryonic cell development and in tumour development. This text reviews the latest molecular studies of cholinesterase expression, structure and function. "Human Cholinesterases and Anticholinesterases" is conveniently divided into three parts, each of which presents different points of view on human cholinesterase research. The first part discusses the biochemical and biological backgound on human CHEs, taking into consideration our recently acquired molecular know-how; the second displays an updated report of the molecular characterization of the human cholinesterase genes and their multi-leveled regulation; and the...

Cholinesterase Inhibitors in Alzheimer's Disease

Cholinesterase Inhibitors in Alzheimer's Disease
by G. Mallarkey (Author), Gordon Mallarkey (Editor)


Book by Mallarkey, G.

Organophosphates Chemistry, Fate, and Effects

Organophosphates Chemistry, Fate, and Effects
by Janice E. Chambers (Editor), Patricia E. Levi (Editor)


This volume pulls together a wealth of up-to-date information on the toxicology of this diverse and ubiquitous class of insecticides. Leading experts review the reactivity of organophosphorus compounds with cholinesterase, as well as their metabolism and biological effects on humans and other nontarget organisms. The book not only covers the anticholinesterase actions of organophosphates, but also other, presumably independent, effects, such as teratogenicity, delayed neuropathy, immunotoxicity, and behavioral toxicity.Offers crucial overviews of chemical and biochemical reactivity and biological responsiveness of mainly nontarget organismsReviews new developments in assessment of metabolism and disposition of organophosphorus compoundsExamines organophosphorus compound-induced toxicity...

Alzheimer's Disease Pocket Guide: Full Illustrated

Alzheimer's Disease Pocket Guide: Full Illustrated
by HC-HealthComm


Table of Contents
Introduction
Diagnosis
Diagnostic Tests
Ten Warning Signs
New Diagnostic Criteria and Guidelines for Alzheimer's Disease
Alzheimer's Disease Progression
Summary of New Diagnostic Criteria and Guidelines for Alzheimer’s Disease
Dementia Due to Alzheimer's Disease
Mild Cognitive Impairment (MCI) Due to Alzheimer's Disease
Preclinical Alzheimer's Disease
Biomarkers
Neuropathologic Assessment of Alzheimer's
Brain Scans Help Identify Alzheimer´s
Risk Factors for Alzheimer’s Disease
Cardiovascular Disease
Cerebrovascular Disease
Physical Frailty
Exercise
“Good” and “Bad” Cholesterol
High Energy Diets, Diabetes and Obesity
Parts of the Brain
Spouse and...

Anticholinesterase Pesticides: Metabolism, Neurotoxicity, and Epidemiology

Anticholinesterase Pesticides: Metabolism, Neurotoxicity, and Epidemiology
by Tetsuo Satoh (Editor), Ramesh C. Gupta (Editor)


This book offers an important reference source about the most common classes of pesticides for researchers engaged in the area of neurotoxicology, metabolism, and epidemiology. The book presents details about thorough characterization of target and non-target enzymes and proteins involved in toxicity and metabolism; and epidemiology of poisonings and fatalities in people from short- and long- term exposures to these pesticides in different occupational settings on an individual country basis as well as on a global basis. The early portion of the book deals with metabolism, mechanisms and biomonitoring of anticholinesterase pesticides, while the later part deals with epidemiological studies, regulatory issues, and therapeutic intervention.

© 2016 BrightSurf.com